1. Home
  2. NDLS vs BYSI Comparison

NDLS vs BYSI Comparison

Compare NDLS & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Noodles & Company

NDLS

Noodles & Company

HOLD

Current Price

$13.75

Market Cap

68.7M

ML Signal

HOLD

Logo BeyondSpring Inc.

BYSI

BeyondSpring Inc.

HOLD

Current Price

$1.72

Market Cap

58.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NDLS
BYSI
Founded
1995
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
68.7M
58.4M
IPO Year
2013
2016

Fundamental Metrics

Financial Performance
Metric
NDLS
BYSI
Price
$13.75
$1.72
Analyst Decision
Hold
Analyst Count
1
0
Target Price
N/A
N/A
AVG Volume (30 Days)
28.8K
23.7K
Earning Date
05-06-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$495,089,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
0.37
N/A
52 Week Low
$0.47
$1.18
52 Week High
$13.95
$3.44

Technical Indicators

Market Signals
Indicator
NDLS
BYSI
Relative Strength Index (RSI) 63.74 58.00
Support Level $0.59 $1.69
Resistance Level $13.95 $1.83
Average True Range (ATR) 1.02 0.13
MACD 0.06 0.02
Stochastic Oscillator 90.15 85.00

Price Performance

Historical Comparison
NDLS
BYSI

About NDLS Noodles & Company

Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services. It is focused on offering customers flavorful, cooked-to-order dishes in a warm and welcoming environment at an attractive value. It has approximately 340 company-owned restaurants and 83 franchise restaurants in 31 states.

About BYSI BeyondSpring Inc.

BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.

Share on Social Networks: